Table 2 Multivariate analysis of transplantation outcome
Outcome | HR | 95% CI | p | |
|---|---|---|---|---|
RI | FLAMSA (ref) | 1 | ||
TBF | 0.9 | 0.6–1.4 | 0.6 | |
FT | 0.8 | 0.5–1.2 | 0.2 | |
Age (per 10 years) | 0.9 | 0.8–0.9 | 0.005 | |
Relapse vs prim. ref | 1.3 | 1.1–1.6 | 0.01 | |
Patient CMV pos. | 1.3 | 1.03–1.7 | 0.03 | |
NRM | FLAMSA (ref) | 1 | ||
TBF | 1.5 | 0.8–2.7 | 0.17 | |
FT | 1.2 | 0.7–2.1 | 0.5 | |
Age (per 10 years) | 1.3 | 1.1–1.5 | 0.002 | |
MSD (reference) | 1 | |||
UD 10/10 | 1.5 | 0.9–2.3 | 0.08 | |
UD 9/10 | 1.8 | 1.1–2.9 | 0.03 | |
LFS | FLAMSA (ref) | 1 | ||
TBF | 1.1 | 0.7–1.5 | 0.7 | |
FT | 0.9 | 0.6–1.3 | 0.6 | |
Patient CMV pos. | 1.4 | 1.1–1.7 | 0.005 | |
OS | FLAMSA (ref) | 1 | ||
TBF | 1.2 | 0.8–1.7 | 0.3 | |
FT | 0.8 | 0.6–1.2 | 0.4 | |
KPS ≥ 80% | 0.7 | 0.5–0.9 | 0.01 | |
Patient CMV pos. | 1.3 | 1.1–1.6 | 0.02 | |
GRFS | FLAMSA (ref) | 1 | ||
TBF | 0.9 | 0.7–1.4 | 0.9 | |
FT | 0.8 | 0.6–1.07 | 0.13 | |
KPS ≥ 80% | 0.7 | 0.5–0.9 | 0.01 | |
Patient CMV pos. | 1.2 | 1.004–1.5 | 0.05 | |
ATG used | 0.8 | 0.6–1.01 | 0.06 | |
aGVHD III–IV | FLAMSA (ref) | 1 | ||
TBF | 0.9 | 0.4–2.1 | 0.8 | |
FT | 0.7 | 0.3–1.6 | 0.4 | |
KPS ≥ 80% | 0.5 | 0.3–1.02 | 0.06 | |
MSD (reference) | 1 | |||
UD 10/10 | 1.6 | 0.8–2.9 | 0.16 | |
UD 9/10 | 3.6 | 1.9–6.9 | < 0.001 | |
Female D to male R | 1.7 | 1.01–2.9 | 0.045 | |
ATG used | 0.4 | 0.2–0.9 | 0.018 | |
cGVHD | FLAMSA (ref) | 1 | ||
TBF | 1.7 | 0.7–4.1 | 0.2 | |
FT | 0.7 | 0.3–1.6 | 0.4 | |
Age (per 10 years) | 0.8 | 0.7–0.9 | 0.03 | |
ATG used | 0.4 | 0.2–0.8 | 0.006 | |
Severe cGVHD | FLAMSA (ref) | 1 | ||
TBF | 1.4 | 0.6–3.3 | 0.4 | |
FT | 0.6 | 0.2–1.3 | 0.2 | |
Donor CMV pos. | 1.7 | 0.99–2.7 | 0.05 | |
ATG used | 0.4 | 0.2–0.7 | 0.005 | |